Rajesh Kumar
Stock Analyst at HSBC
(2.52)
# 2,125
Out of 5,182 analysts
33
Total ratings
45.45%
Success rate
4.64%
Average return
Main Sectors:
Stocks Rated by Rajesh Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Downgrades: Reduce | $1,070 → $850 | $963.33 | -11.76% | 4 | Mar 17, 2026 | |
| PFE Pfizer | Maintains: Buy | $29 → $32 | $26.33 | +21.53% | 2 | Mar 17, 2026 | |
| BIIB Biogen | Maintains: Reduce | $143 → $150 | $187.06 | -19.81% | 2 | Mar 17, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Hold | $53 → $60 | $58.22 | +3.06% | 3 | Mar 17, 2026 | |
| ABBV AbbVie | Upgrades: Buy | $225 → $265 | $206.60 | +28.27% | 5 | Dec 10, 2025 | |
| NVO Novo Nordisk | Downgrades: Hold | n/a | $43.88 | - | 3 | Nov 24, 2025 | |
| IQV IQVIA Holdings | Upgrades: Buy | $195 → $235 | $157.77 | +48.95% | 2 | Oct 9, 2025 | |
| KDP Keurig Dr Pepper | Upgrades: Buy | $36 → $42 | $29.09 | +44.38% | 1 | Apr 25, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $660 → $670 | $469.21 | +42.79% | 3 | Apr 30, 2024 | |
| DHR Danaher | Upgrades: Buy | $250 → $280 | $175.15 | +59.86% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $460 | $368.78 | +24.74% | 2 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $34.95 | -62.80% | 1 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Reduce | $97 | $45.37 | +113.80% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $124 | $97.54 | +27.13% | 1 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $123 | $112.16 | +9.66% | 1 | Jul 14, 2023 |
Eli Lilly and Company
Mar 17, 2026
Downgrades: Reduce
Price Target: $1,070 → $850
Current: $963.33
Upside: -11.76%
Pfizer
Mar 17, 2026
Maintains: Buy
Price Target: $29 → $32
Current: $26.33
Upside: +21.53%
Biogen
Mar 17, 2026
Maintains: Reduce
Price Target: $143 → $150
Current: $187.06
Upside: -19.81%
Bristol-Myers Squibb Company
Mar 17, 2026
Maintains: Hold
Price Target: $53 → $60
Current: $58.22
Upside: +3.06%
AbbVie
Dec 10, 2025
Upgrades: Buy
Price Target: $225 → $265
Current: $206.60
Upside: +28.27%
Novo Nordisk
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $43.88
Upside: -
IQVIA Holdings
Oct 9, 2025
Upgrades: Buy
Price Target: $195 → $235
Current: $157.77
Upside: +48.95%
Keurig Dr Pepper
Apr 25, 2025
Upgrades: Buy
Price Target: $36 → $42
Current: $29.09
Upside: +44.38%
Thermo Fisher Scientific
Apr 30, 2024
Maintains: Buy
Price Target: $660 → $670
Current: $469.21
Upside: +42.79%
Danaher
Apr 17, 2024
Upgrades: Buy
Price Target: $250 → $280
Current: $175.15
Upside: +59.86%
Apr 4, 2024
Upgrades: Hold
Price Target: $460
Current: $368.78
Upside: +24.74%
Dec 18, 2023
Initiates: Buy
Price Target: $13
Current: $34.95
Upside: -62.80%
Jul 14, 2023
Initiates: Reduce
Price Target: $97
Current: $45.37
Upside: +113.80%
Jul 14, 2023
Initiates: Buy
Price Target: $124
Current: $97.54
Upside: +27.13%
Jul 14, 2023
Initiates: Hold
Price Target: $123
Current: $112.16
Upside: +9.66%